Motus GI Holdings, Inc. · OTC:MOTS
Motus GI — Investor Presentation (November 2018)
25 slides from Motus GI's investor presentation, Nov 15, 2018
Slide 1: Developing Breakthrough Solutions for Endoscopy
www.motusgi.com NASDAQ: MOTS Developing Breakthrough Solutions for Endoscopy November 2018
Slide 2: Forward-Looking Statements
Forward - Looking Statements 2 This presentation contains certain forward - looking statements, including those relating to the Company’s product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operatio
Slide 3: Developing Breakthrough Solutions for GI Endoscopy
Developing Breakthrough Solutions for GI Endoscopy 3 FDA - Cleared Flagship Product, Pure - Vu® System, Enables Rapid Bowel Cleansing During Colonoscopy Procedures • Targeting multi - billion dollar market opportunity • Leveraging existing hospital reimbursement (DRG) • Developing key clinical and h
Slide 4: Targeting Multi-Billion Dollar Inpatient Market Opportunity
4 Targeting Multi - Billion Dollar Inpatient Market Opportunity 1: HRA Healthcare Research & Analytics - Market Research, May 2015 US Inpatient Market Worldwide Inpatient Market ~1.5M 1 Colonoscopy procedures/year Colonoscopy procedures/year ~3.8M 1 1: HRA Healthcare Research & Analytics - Market Re
Slide 5: Pure-Vu video
PUREVL' ty MOTUS” AY VIDEO >
Slide 6: Pure-Vu Overview
Pure - Vu® Overview 6 Workstation Disposable Sleeve on Scope Standard colonoscope Irrigation ports Evacuation port Integrates easily with current scopes and physician workflow Highly effective pulsed vortex irrigation to break up colon content Efficient evacuation with anti - clogging Auto Purge tec
Slide 7: Demonstrated Outstanding Cleansing Performance in Patients with Partially Prepped Colons
Demonstrated Outstanding Cleansing Performance in Patients with Partially Prepped Colons 7 Before Pure - Vu® After Pure - Vu® 5.0 2.8 3.7 8.8 8.5 8.9 0 1 2 3 4 5 6 7 8 9 10 Pure-Vu® Multicenter Study 1 (N=48) Pure-Vu® Multicenter Study 2 (N=46) Pure-Vu® Single-Center Study 3 (N=46) BBPS Score BBPS R
Slide 8: Inpatient Colonoscopy Procedures
Inpatient Colonoscopy Procedures 8 Lower GI Bleeds Severe Anemia Unknown Abdominal Pain Infection Existing reimbursement covers entire episode of care as a fixed bundled payment (DRG) Successful Exam and Patient Discharged ER, ICU and Hospital Ward 3.8M Worldwide Patients Annually 1 Bowel Prep and P
Slide 9: Bowel Prep Challenges Represent Significant Burden
Bowel Prep Challenges Represent Significant Burden 9 Repeat Procedures 55% Insufficiently Prepped 1 24 Hour Bowel Prep Repeat Bowel Prep Inpatient Colonoscopy Occupied Bed Not Available for New Patients Insufficient bowel prep leads to frequent delays, procedure failures and increased costs 1: Keswa
Slide 10: Enabling Rapid and Predictable Colonoscopy
Enabling Rapid and Predictable Colonoscopy Potential to Reduce Direct Costs for Inpatient Colonoscopy 10 Accelerated Bed Turn - over for New Patients Potential to become new standard of care Pure - Vu® has the potential to: • Reduce time to successful bowel prep • Eliminate repeat procedures • Impro
Slide 11: REDUCE Study – Topline Results on Track for Q1 2019
REDUCE Study – Topline Results on Track for Q1 2019 11 Primary Endpoint: • BBPS index - improved bowel cleansing Enables First Time Procedure Success 100 Patient, single - arm, multi - center, prospective study Key Health Economic Endpoint: • Time to successful exam vs. current standard Currently En
Slide 12: EXPEDITE Study – Expected to Initiate end of 2018
EXPEDITE Study – Expected to Initiate end of 2018 12 Accelerated Bed Turn - over for New Patients Key Study Objectives: • BBPS index - improved bowel cleansing • % of successful colonoscopy with minimal preparation • Improve diagnostic yield Shorten Time to Colonoscopy Procedure and Diagnosis Emerge
Slide 13: Commercialization Strategy: Launch Q2 2019
Commercialization Strategy: Launch Q2 2019 13 Methodical, Disciplined Approach to Drive Rapid VAC Approval • REDUCE Study • EXPEDITE Study • Market Development Accounts Value Analysis Committee Approval & Purchase • Physician Champions • GI/Nursing Staff • Hospital Administration • Tailored Value Ca
Slide 14: Economic Calculator Demonstrates The Value of Pure-Vu
Economic Calculator Demonstrates The Value of Pure - Vu® 14 Savings do not include additional potential hospital revenues created through accelerated bed turnover Potential Total Savings Net of Pure - Vu® Investment $3,742 $1,475,662 $3,636 Potential Savings / Each Delayed Procedure Potential Saving
Slide 15: Commercial Expansion to Support Full Launch in Q2 2019
Commercial Expansion to Support Full Launch in Q2 2019 15 Sales Team (10) Northwest So - Cal Gulf Coast Southwest Midwest Ohio Valley New York Northeast Southeast Mid - Atlantic MA WA OR CA AK MT ID NV UT WY CO NV AZ ND SD NE KS OK TX MN IA WI IL MO AR LA MS AL GA FL MI OH IN KY TN SC NC VA WV WPA E
Slide 16: ~$3 Billion Potential Direct Hospital Cost Savings in US
~$3 Billion 1 Potential Direct Hospital Cost Savings in US Driving Cost Savings to Support Value Based Pricing 16 • Potential direct hospital cost savings based on shortened length of stay* • ~$2,000 per patient in US 1 • ~$1,000 per patient in key OUS markets 2 • Prospective value based pricing • D
Slide 17: Significant Follow on Expansion Opportunities
17 Significant Follow on Expansion Opportunities Inpatient: Upper GI Bleed Endoscopy (Target Launch Q1 2021) Value: • Remove clots and debris to provide clear field of view • Leverage existing hospital call points, doctors and sales force Market Opportunity 1M 1 Worldwide Procedures Annually Potenti
Slide 18: Opportunity to Become Standard of Care in Key Endoscopy Segments
Opportunity to Become Standard of Care in Key Endoscopy Segments 18 1: HRA Healthcare Research & Analytics - Market Research, May 2015 2: El - Tawil AM, World J Gastroenterol, 2012 Mar 21;18(11):1154 - 8; incorporates company’s current estimate 3: Hassan C. et.al., Clinical Gastroenterology and Hepa
Slide 19: Management Team
Management Team 19 Timothy P. Moran Chief Executive Officer Seasoned commercial and operating executive with experience in both large publicly - traded and private equity - backed companies Mark Pomeranz President and Chief Operating Officer 30 years of experience in the medical device industry with
Slide 20: Board of Directors
Board of Directors 20 David Hochman Chairman Chairman & CEO, Orchestra BioMed; Director of Corbus and Adgero Gary Jacobs Director Managing Director, Jacobs Investment Company Shervin Korangy Director CFO and Chief Strategy Officer of Beaver - Visitec International Timothy P. Moran Chief Executive Of
Slide 21: Physician Advisory Board
Physician Advisory Board 21 Gerald Bertiger, MD Steven A. Edmundowicz, MD, FASGE Prof. Ian Gralnek, MD, MSHS, FASGE David Lieberman, MD, FACG Ori Segol, MD Prof. Peter D. Siersema, MD, Phd, FASGE Seth A. Gross, MD, FACG, FASGE, AGAF Managing Partner and President of Hillmont, GI, P. C.; Section Chie
Slide 22: Financial Profile
22 Financial Profile: NASDAQ: MOTS Market Cap: ~$54M 1 Common Shares Outstanding: ~15.6M 2 Average Daily Volume: ~59K 1 Cash Balance: ~$11.6M 2 1: Based on November 12, 2018 closing price of $3.48 per share 2: As of September 30, 2018
Slide 23: Near Term Value Catalysts: Next Three Quarters
Near Term Value Catalysts: Next Three Quarters 23 • Present data from prep reduction study • PR first clinical cases using SLIM • Finalize GEN 2 product design • Submit interim data from REDUCE for DDW 2018 Q4 2019 Q1 2019 Q2 • Complete REDUCE inpatient study • Initiate EXPEDITE inpatient study • Re
Slide 24: Investment Highlights
24 Investment Highlights Revolutionizing the large and growing GI endoscopy market Inpatient market represents multi - billion dollar opportunity Building a strong foundation of clinical and health economic data Opportunity to become standard of care in key endoscopy segments Highly - experienced ma
Slide 25: Thank you
www.motusgi.com NASDAQ: MOTS Thank you info@motusgi.com
Motus GI Holdings — Investor Presentation (November 2018) on 6ix